Deferred Income Tax Expense (Benefit) in USD of Finch Therapeutics Group, Inc. from Q1 2022 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Finch Therapeutics Group, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2022 to Q1 2024.
  • Finch Therapeutics Group, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $0.000.
  • Finch Therapeutics Group, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$3.46M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), Annual (USD)

Finch Therapeutics Group, Inc. Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $0 +$3.46M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q1 2023 -$3.46M -$3.46M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q1 2022 $0 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10

Finch Therapeutics Group, Inc. Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$3.46M -$3.46M Jan 1, 2023 Dec 31, 2023 10-K 2024-03-25
2022 $0 Jan 1, 2022 Dec 31, 2022 10-K 2024-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.